Home
Cytori Therapeutics

Cytori Therapeutics Market Share Analysis for November 2025

One may contact Lorem Cytori in several ways - email, phone, mail, or by completing and submitting the form below.

Health > Biotechnology and Pharmaceuticals

Domaincytori.com

Year Founded1997

Employees51 - 200

Annual Revenue$2M - $5M

Cytori Therapeutics

Cytori Therapeutics (including company regionals)

cytori.com

See more website traffic and engagement information

Cytori Therapeutics Revenue up to November 2025 is 2M - 5M

revenue generated by Cytori Therapeutics top domains

Cytori Therapeutics top domains revenue over 3 years

Revenue for Cytori Therapeutics top domains

cytori.com2M - 5M

See more with Sales Intelligence

Total visits to Cytori Therapeutics's top domains

Understand Cytori Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

cytori.com311

See more with Sales Intelligence

Avg. visit duration in Cytori Therapeutics's top domains

Analyze Cytori Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Cytori Therapeutics's top domains

See how Cytori Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

cytori.com1.04

See more with Sales Intelligence

Cytori Therapeutics top competitors by domain

Top similar sites in November 2025, ranked by their affinity

cytokinetics.comCompany NameCytokineticsEmployees501 - 1000HQUnited States, California, South San FranciscoAnnual revenue$50M - $75MTotal visits20KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Cytori Therapeutics

These are the website technologies, by industry, used by Cytori Therapeutics top domains

Email Services (2)

G Suite

Online Forms (2)

Gravity Forms

Social (2)

Instagram

Content Management System (1)

WordPress

More Technologies

5

See all

News & Signals from Cytori Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCytori Therapeutics partners with Oxford Finance LLC.On December 31, 2018, Cytori Therapeutics, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its existing Loan and Security Agreement, dated May 29, 2015, as amended (the “Loan Agreement”), with Oxford Finance LLC (“Oxford”), as collateral agent, and the lenders party thereto, including Oxford (the “Lenders”), to which, among other things, Oxford and the Lenders agreed to extend the maturity date from June 1, 2019 to June 1, 2020.

NewsCytori Therapeutics is developing ATI-0918 on Nov 14th '19.Cytori is developing its lead chemotherapy drug, ATI-0918, a generic version of pegylated liposomal doxorubicin hydrochloride, with the goal of submitting a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) next year.

NewsCytori Therapeutics hired Marc Hedrick as CEO on Jan 1st '14.In 2014 Marc Hedrick was appointed CEO of Cytori Therapeutics Inc ( NASDAQ:CYTX ).